2929 Pharma Foods International
- 896
- -11-1.21%
Pharma Foods International News
Pharma F---discovered the performance improvement effect of ingesting GABA in e-sports
Pharma Foods ＜2929＞ announced on the 23rd that it has discovered the performance improvement effect of e-sports due to GABA intake. Research was conducted on the effects of GABA intake during e-sports in collaboration with lecturer Furumon Ryosuke of Nishinippon Institute of Technology and Associate Professor Goichi Hagiwara of Kyushu Sangyo University. According to research, (1) as a result of electroencephalogram measurements during minigame play for MOBA genre games for training, a deep state of concentration (zone) is maintained in the middle and end of the game due to GABA intake
Pharma F Research Memo (12): Shareholder returns are estimated to have a total return ratio of 20%, including share repurchases
■Pharma Foods ＜2929＞ Growth Strategy 5. Shareholder return measures Regarding return of profits to shareholders, the basic policy is to actively enhance dividends, etc. as return measures for shareholders while actively expanding investment in research and development, advertising, M&A, etc. under a business policy that balances corporate growth and profitability. Based on this policy, shareholders have a total return ratio of 20%, including share buybacks, taking into account the balance between promoting growth investments, ensuring financial soundness, and strengthening shareholder returns
Pharma F Research Memo (11): Creating new markets in the fields of “textiles,” “battery materials,” and “biostimulants”
■Pharma Foods ＜2929＞ Growth Strategy 3. New market creation In the health market, which is an expansion trend, brand strengthening, overseas market development (US market development, Chinese market development through cross-border EC, Southeast Asian market development through halal certification), deepening mail order business in the domestic market (development of new products and services utilizing D2C platforms with over 1 million people), and business model transformation from BtoB to BtoC (major drug company brand products
Pharma F Research Memo (10): Aiming for sales of 100 billion yen for the fiscal year ending 2026/7 with “New Value Creation 1K”
■Growth Strategy 1. The Mid-Term Management Plan 2026 Pharma Foods ＜2929＞ sets “New Value Creation 1K” in the “Mid-Term Management Plan 2026” (2022/7 to 2026/7), and aims for sales of 100 billion yen for the 2026/7 fiscal year through efforts to create new value (new products, new markets, new organizations). The breakdown of numerical sales targets is 70 billion yen for growth in existing businesses, 30 billion yen for new value creation, and average sales growth rate by the 2026/7 fiscal year as a commitment
Pharma F Research Memo (8): The BtoB business expanded steadily, and the BtoC business declined but turned into a surplus
■Performance Trends of Pharma Foods ＜2929＞ 2. Trends by segment (1) BtoB business In the BtoB business, sales increased 2.5% from the same period last year to 4,171 million yen, and segment profit (operating profit before adjustments for company-wide expenses, etc.) increased 6.1% from the same period last year to 743 million yen. Although shipments of some Meiji Pharmaceutical products were affected by the Reiwa 6 Noto Peninsula Earthquake, sales and profits increased steadily, centering on the main force “Pharma Gaba (R).” Sales by item were the same for functional materials 16.
Pharma F Research Memo (7): The second quarter of the fiscal year ending 2024/7 turned into a surplus
■Financial Trends 1. Consolidated financial results summary for the 2nd quarter of the fiscal year ending 2024/7 Pharma Foods ＜2929＞ consolidated financial results for the second quarter of the fiscal year ending 2024/7 were sales of 31,652 million yen, operating income of 1,535 million yen (loss of 883 million yen in the same period last year), ordinary profit of 1,542 million yen (loss of 912 million yen), and quarterly net profit attributable to parent company shareholders was 768 million yen (loss of 914 million yen). As for sales, the BtoB business has steadily expanded
Pharma F Research Memo (5): BtoC business expands product lineups such as “pneumo (R) hair growth agents,” etc., and new products are also growing
■Business Overview 3. BtoC business The BtoC business sells pharmaceuticals/quasi-drugs, supplements, and cosmetics containing functional ingredients unique to Pharma Foods ＜2929＞ as a “mail-order business for inventing companies.” The sales form is direct sales to consumers in a mail order form or wholesale sales to shopping specialty channels. Also, Meiji Pharmaceutical's “repeat mail order business” was added from the 2nd quarter of the 2022/7 fiscal year. Sales by category for the fiscal year ending 2023/7 are medical
Pharma F Research Memo (4): The main force in the BtoB business “Pharma Gaba (R)” has the top share of GABA production
■Pharma Foods ＜2929＞ Business Overview 2. BtoB business The BtoB business carries out research and development and manufacture of functional materials, health foods, pharmaceuticals, etc., and sells them to food and pharmaceutical manufacturers, distributors, etc. Main functional material products include “Pharma Gaba (R),” “Bone Pep (R),” “Cerepron (R) (Cerepron),” “Lampep (R),” “Pharma Biomix,” and “HGP (R).” Functional products are conventional OEMs and cross-border E
Pharma F Research Memo (3): Research and development type healthcare manufacturer developing BtoB business, biomedical business, etc.
■Business Overview 1. Research and development healthcare manufacturer Pharma Foods ＜2929＞ has set a mission to “advance medical and dietary research and contribute to people,” and aims to realize a sustainable, healthy, and happy society for people. To achieve this, we are carrying out research and development of functional materials and pharmaceuticals that act on “immunity,” “aging,” and “nerves,” and we are widely providing unique research results and products to society in the three businesses of BtoB business, BtoC business, and biomedical business.
Pharma F Research Memo (2): Creation of food ingredients with clear functions useful for maintaining health and improving quality of life
■Company Overview 1. Company Overview Pharma Foods ＜2929＞ is a biotechnology company aiming for “Pharma Foods” (Pharma Foods) consisting of a fusion of “pharmaceuticals” (pharmaceuticals) and “foods” (Foods), with a basic management policy to contribute to people's health. Using “immunity,” “aging,” and “nerves,” the three elements involved in life activity and health maintenance as development concepts, from familiar ingredients such as eggs, milk, green tea, rice, and lactic acid bacteria to 3 elements
Pharma F -- a biotechnology company aiming to become “Pharma Foods” through the fusion of pharmaceuticals and food
Pharma Foods ＜2929＞ is a biotechnology company aiming for “Pharma Foods” (Pharma Foods) consisting of a fusion of “pharmaceuticals” (Pharmaceuticals) and “foods” (Foods), with a basic management policy to contribute to people's health. A food ingredient that clearly has functions useful for maintaining health and improving quality of life (QOL: Quality of Life) using unique technology based on scientific evidence that is particular about ingredients derived from nature
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1911＞ Sumitomo Hayashi 4798 5053 ＜1928＞ Sekisui House 3523 3564 ＜2737＞ Tomen Deva 6630 6960 ＜2914＞ JT 4129 4162 ＜2929＞ Pharma F 881 978 ＜3198＞ SFP
Pharma Foods --- established a joint research course with Tohoku University Graduate School of Medicine to accelerate research and development of antibody drugs against intractable cancers
Pharma Foods ＜2929＞ announced on the 1st that it has established the “PFI Antibody Drug Joint Research Course” (representative researcher: Professor Yukinari Kato) in collaboration with Tohoku University Graduate School of Medicine. Professor Yukinari Kato has succeeded in creating many antibodies and deriving companies so far using the “CasmAb (R) method,” a preparation technology for cancer-specific antibodies, and some of them have already progressed to clinical clinical trials. The company has its own unique antibody production technology “AlaGene (R) technology,” and Professor Yukinari Kato”
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜2593＞ Itoen 3698 3613 ＜2929＞ Pharma F 950 861 ＜2980＞ SREHD 4200 3980 ＜3548＞ Baroque 759 737 ＜4481＞ base 3510 3235 ＜
Pharma Foods International Return to the Black in Fiscal Q1
Pharma Foods International (TYO:2929) returned to black in the fiscal first quarter ended Oct. 31, with a profit attributable to owners of the parent of 286 million yen, from a loss of 1.82 billion ye
Pharma Foods International Turns to Fiscal Q1 Loss on Higher Expenses
04:46 AM EST, 12/08/2022 (MT Newswires) -- Pharma Foods International (TYO:2929) swung to an attributable loss for the first quarter of fiscal 2023 despite a 35.1% rise in net sales due to a surge in
Analysis
Price Target
No Data
